Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial
- PMID: 11239184
- DOI: 10.1161/01.str.32.3.661
Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial
Abstract
Background and purpose: Little is known in regard to cerebral arterial reocclusion after successful thrombolysis. In the absence of arteriographic information, the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial investigators prospectively identified clinical deterioration following improvement (DFI) as a possible surrogate marker of cerebral arterial reocclusion after rt-PA-induced recanalization. Also, we identified any significant clinical deterioration (CD) even if not preceded by improvement. This observational analysis was designed to determine the incidence of DFI and CD in each treatment group, to identify baseline or posttreatment variables predictive of DFI or CD, and to determine any relationship between DFI, CD, and clinical outcome.
Methods: DFI was defined as any 2-point deterioration on the NIH Stroke Scale after an initial 2-point improvement after treatment. CD was defined as any 4-point worsening after treatment compared with baseline. All data were collected prospectively by investigators blinded to treatment allocation. A noncontrast brain CT was mandated when a 2-point deterioration occurred. All cases were validated by a central review committee.
Results: DFI was identified in 81 of the 624 patients (13%); 44 were treated with rt-PA and 37 were treated with placebo (P:=0.48). DFI occurred more often in patients with a higher baseline NIH Stroke Scale score. CD within the first 24 hours occurred in 98 patients (16% of all patients); 43 were given rt-PA and 55 were given placebo (P:=0.19). Baseline variables associated with CD included a less frequent use of prestroke aspirin and a higher incidence of early CT changes of edema or mass effect or dense middle cerebral artery sign. Patients with CD had higher rates of increased serum glucose and fibrin degradation products, and they also had higher rates of symptomatic intracranial hemorrhage and death. Patients who experienced either DFI or CD were less likely to have a 3-month favorable outcome.
Conclusions: We found no association between DFI, CD, and rt-PA treatment, and no clinical evidence to suggest reocclusion. Deterioration was strongly associated with stroke severity and poor outcome and was less frequent in patients whose stroke occurred while they were on aspirin.
Similar articles
-
Early neurological deterioration within 24 hours after intravenous rt-PA therapy for stroke patients: the Stroke Acute Management with Urgent Risk Factor Assessment and Improvement rt-PA Registry.Cerebrovasc Dis. 2012;34(2):140-6. doi: 10.1159/000339759. Epub 2012 Aug 1. Cerebrovasc Dis. 2012. PMID: 22854333
-
Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke.Stroke. 2004 Jan;35(1):147-50. doi: 10.1161/01.STR.0000105396.93273.72. Epub 2003 Dec 4. Stroke. 2004. PMID: 14657446
-
Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study.Stroke. 2007 Jan;38(1):69-74. doi: 10.1161/01.STR.0000251800.01964.f6. Epub 2006 Nov 30. Stroke. 2007. PMID: 17138949
-
Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case definitions.Cerebrovasc Dis. 2012;34(2):106-14. doi: 10.1159/000339675. Epub 2012 Aug 1. Cerebrovasc Dis. 2012. PMID: 22868870 Review.
-
Review, historical context, and clarifications of the NINDS rt-PA stroke trials exclusion criteria: Part 1: rapidly improving stroke symptoms.Stroke. 2013 Sep;44(9):2500-5. doi: 10.1161/STROKEAHA.113.000878. Epub 2013 Jul 11. Stroke. 2013. PMID: 23847249 Free PMC article. Review.
Cited by
-
Rt-PA thrombolytic therapy in patients with acute posterior circulation stroke: A retrospective study.Med Int (Lond). 2022 Mar 1;2(2):8. doi: 10.3892/mi.2022.33. eCollection 2022 Mar-Apr. Med Int (Lond). 2022. PMID: 36699100 Free PMC article.
-
Prospective pilot study of tirofiban in progressive stroke after intravenous thrombolysis.Front Neurol. 2022 Oct 4;13:982684. doi: 10.3389/fneur.2022.982684. eCollection 2022. Front Neurol. 2022. PMID: 36267890 Free PMC article.
-
Safety and Efficacy of Endovascular Treatment for Progressive Stroke in Patients With Acute Basilar Artery Occlusion.Front Neurol. 2021 Dec 16;12:774443. doi: 10.3389/fneur.2021.774443. eCollection 2021. Front Neurol. 2021. PMID: 34975733 Free PMC article.
-
Evaluation of Transient Ischemic Attack and Minor Stroke: A Rapid Outpatient Model for the COVID-19 Pandemic and Beyond.Neurohospitalist. 2022 Jan;12(1):38-47. doi: 10.1177/19418744211000508. Epub 2021 Mar 29. Neurohospitalist. 2022. PMID: 34950385 Free PMC article. Review.
-
Fifty Years of Acute Ischemic Stroke Treatment: A Personal History.Cerebrovasc Dis. 2021;50(6):666-680. doi: 10.1159/000519843. Epub 2021 Oct 14. Cerebrovasc Dis. 2021. PMID: 34649237 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical